Vaccine alliance raises $2 billion to buy Covid-19 shots for poor nations

Berkley said $3 billion was still needed for diagnostics and $6.1 billion for therapeutics by the end of 2021

Covid-19 coronavirus
Pfizer and its partner BioNTech expressed an interest in supplying doses to the COVAX facility
Reuters LONDON/GENEVA
2 min read Last Updated : Nov 13 2020 | 5:38 PM IST

By Kate Kelland and Stephanie Nebehay

LONDON/GENEVA (Reuters) - A facility set up by the World Health Organization (WHO) and the GAVI vaccine group has exceeded an interim target of raising more than $2 billion to buy and distribute COVID-19 shots for poorer countries, but said it still needs more.

The GAVI alliance said on Friday that the funds for an advance market commitment (AMC) will allow the COVAX facility to buy an initial one billion vaccine doses for 92 eligible countries which would not otherwise be able to afford them.

"We've seen sovereign and private donors from across the world dig deep and help meet this target," GAVI chief Seth Berkley told reporters, adding that there was an "urgent need" to also finance treatments and diagnostics.

Berkley said $3 billion was still needed for diagnostics and $6.1 billion for therapeutics by the end of 2021.

Another $5 billion will also be needed in 2021 to procure COVID-19 vaccine doses as they come through development and are approved by regulators, GAVI said in a statement.

U.S. drugmaker Pfizer and its partner BioNTech, who this week said their experimental COVID-19 vaccine was 90% effective in initial trials, had expressed an interest in supplying doses to the COVAX facility, Berkley said.

"We continue to advance negotiations with a number of manufacturers in addition to those we've already announced who share our vision of fair and equitable distribution of vaccines," he added.

 

(Corrects date to 2021, paragraph 4)

 

(Reporting by Kate Kelland and Stephanie Nebehay, Editing by Alexander Smith)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineVaccineWorld Health Organization

First Published: Nov 13 2020 | 5:35 PM IST

Next Story